1/26/2010

Ablynx CEO Edwin Moses said the Belgian company expects to launch its first llama-derived nanomedicine as early as 2013 through a partnership with Pfizer. The drug, which was developed from extra-small antibodies from llamas, could replace Pfizer's Enbrel as a blockbuster treatment for rheumatoid arthritis.

Full Story:
Reuters

Related Summaries